Back to Search Start Over

Role of ARHGEF3 as a GEF and mTORC2 Regulator.

Authors :
Khaliq SA
Umair Z
Yoon MS
Source :
Frontiers in cell and developmental biology [Front Cell Dev Biol] 2022 Jan 31; Vol. 9, pp. 806258. Date of Electronic Publication: 2022 Jan 31 (Print Publication: 2021).
Publication Year :
2022

Abstract

Guanine nucleotide exchange factors (GEFs) activate GTPases by stimulating the release of guanosine diphosphate to permit the binding of guanosine triphosphate. ARHGEF3 or XPLN (exchange factor found in platelets, leukemic, and neuronal tissues) is a selective guanine nucleotide exchange factor for Rho GTPases (RhoGEFs) that activates RhoA and RhoB but not RhoC, RhoG, Rac1, or Cdc42. ARHGEF3 contains the diffuse B-cell lymphoma homology and pleckstrin homology domains but lacks similarity with other known functional domains. ARHGEF3 also binds the mammalian target of rapamycin complex 2 (mTORC2) and subsequently inhibits mTORC2 and Akt. In vivo investigation has also indicated the communication between ARHGEF3 and autophagy-related muscle pathologies. Moreover, studies on genetic variation in ARHGEF3 and genome-wide association studies have predicted exciting novel roles of ARHGEF3 in controlling bone mineral density, platelet formation and differentiation, and Hirschsprung disease. In conclusion, we hypothesized that additional biochemical and functional studies are required to elucidate the detailed mechanism of ARHGEF3-related pathologies and therapeutics.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Khaliq, Umair and Yoon.)

Details

Language :
English
ISSN :
2296-634X
Volume :
9
Database :
MEDLINE
Journal :
Frontiers in cell and developmental biology
Publication Type :
Academic Journal
Accession number :
35174167
Full Text :
https://doi.org/10.3389/fcell.2021.806258